Acute renal failure during lisinopril and losartan therapy for proteinuria

Area of Science:

• Nephrology
• Pediatric Nephrology
• Pharmacology

Background:

• Combined therapy using angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) is increasingly recognized for managing proteinuria.
• However, data on the safety and efficacy of this dual-drug approach in pediatric populations remain limited.
• This highlights a gap in understanding its application in younger patients.

Observation:

• A case study details a 7-year-old boy experiencing acute renal function decline and hypotension.
• The patient was concurrently treated with an ACE inhibitor (lisinopril) and an ARB (losartan).
• This adverse event occurred despite the patient having relatively preserved baseline renal function.

Findings:

• The combination of lisinopril and losartan was associated with a significant and acute compromise in renal function.
• Hypotension was a key clinical manifestation accompanying the renal impairment.
• This suggests a potential synergistic adverse effect of dual RAAS blockade in this pediatric case.

Implications:

• Close monitoring of renal function and blood pressure is crucial for pediatric patients receiving combined ACE inhibitor and ARB therapy.
• The findings underscore the need for further research into the safety profile and optimal use of dual renin-angiotensin-aldosterone system blockade in children.
• This case serves as a critical reminder for clinicians regarding potential risks even in seemingly stable pediatric patients.